Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 828

1.

Use of beta-blockers in patients with an implantable cardioverter defibrillator.

LaPointe NM, Stafford JA, Pappas PA, Al-Khatib SM, Anstrom KJ.

Ann Pharmacother. 2009 Jul;43(7):1189-96. doi: 10.1345/aph.1M140. Epub 2009 Jun 30.

PMID:
19567655
2.

A comparison of outcomes for patients receiving implantable cardioverter defibrillators for primary vs secondary-prevention.

Giedrimas A, Giedrimiene D, Guertin D, White CM, Clyne CA, Kluger J.

Conn Med. 2008 Jun-Jul;72(6):329-33.

PMID:
18610705
3.

Predictors of appropriate implantable cardioverter defibrillator (ICD) therapy in primary prevention patients with ischemic and nonischemic cardiomyopathy.

Verma A, Sarak B, Kaplan AJ, Oosthuizen R, Beardsall M, Wulffhart Z, Higenbottam J, Khaykin Y.

Pacing Clin Electrophysiol. 2010 Mar;33(3):320-9. doi: 10.1111/j.1540-8159.2009.02566.x. Epub 2009 Oct 1.

PMID:
19796352
4.

The role of implantable cardioverter defibrillator for primary vs secondary prevention of sudden death in patients with idiopathic dilated cardiomyopathy.

Zecchin M, Di Lenarda A, Proclemer A, Faganello G, Facchin D, Petz E, Sinagra G.

Europace. 2004 Sep;6(5):400-6. Erratum in: Europace. 2005 Jan;7(1):91.

5.

Clinical course and long-term follow-up of patients receiving implantable cardioverter-defibrillators.

Tandri H, Griffith LS, Tang T, Nasir K, Zardkoohi O, Reddy CV, Capps M, Calkins H, Donahue JK.

Heart Rhythm. 2006 Jul;3(7):762-8. Epub 2006 Mar 27.

PMID:
16818202
6.

[The implantable cardioverter-defibrillator and hypertrophic cardiomyopathy. Experience at three centers].

Marín F, Gimeno JR, Payá E, García-Alberola A, Pérez-Alvarez L, Fernández X, de la Morena G, Sogorb F, Castro-Beiras A, Valdés M, Martínez JG, Monserrat L.

Rev Esp Cardiol. 2006 Jun;59(6):537-44. Spanish.

7.

Indications for internal cardioverter defibrillator implantation predict time to first shock and the modulating effect of beta-blockers.

Hreybe H, Bedi M, Ezzeddine R, Barrington W, Jain S, Ngwu O, Saba S.

Am Heart J. 2005 Nov;150(5):1064.

PMID:
16290997
8.

Underutilization of beta-blockers in patients undergoing implantable cardioverter-defibrillator and cardiac resynchronization procedures.

Hauptman PJ, Swindle JP, Masoudi FA, Burroughs TE.

Circ Cardiovasc Qual Outcomes. 2010 Mar;3(2):204-11. doi: 10.1161/CIRCOUTCOMES.109.880450. Epub 2010 Mar 2.

9.

[Primary and secondary prevention of sudden cardiac death in the ICD Registry-Latin America].

Ramos JL, Muratore C, Pachón Mateos JC, Rodríguez A, González Hermosillo A, Asenjo R, Rodríguez D, Galvao S, Duque M, Escudero J, Reyes Caorsi W, Cuvillier E, Maloney J.

Arch Cardiol Mex. 2008 Oct-Dec;78(4):400-6. Spanish.

PMID:
19205548
10.

Quality of life among implantable cardioverter-defibrillator recipients in the primary prevention therapeutic era.

Groeneveld PW, Matta MA, Suh JJ, Yang F, Shea JA.

Pacing Clin Electrophysiol. 2007 Apr;30(4):463-71.

PMID:
17437568
11.

Predictors of appropriate implantable defibrillator therapies in patients with arrhythmogenic right ventricular dysplasia.

Piccini JP, Dalal D, Roguin A, Bomma C, Cheng A, Prakasa K, Dong J, Tichnell C, James C, Russell S, Crosson J, Berger RD, Marine JE, Tomaselli G, Calkins H.

Heart Rhythm. 2005 Nov;2(11):1188-94.

PMID:
16253908
12.

Appropriate ICD therapy in patients with idiopathic dilated cardiomyopathy: long term follow-up.

Karaoguz R, Maydanozcu S, Altun T, Güldal M, Akyürek O, Erol C.

Int Heart J. 2006 Sep;47(5):763-73.

13.

Effect of concomitant antiarrhythmic therapy on survival in patients with implantable cardioverter defibrillators.

Ho AT, Pai SM, Timothy P, Pai RG.

Pacing Clin Electrophysiol. 2005 Jul;28(7):647-53.

PMID:
16008799
14.

Efficacy of implantable cardioverter defibrillator therapy for primary and secondary prevention of sudden cardiac death in hypertrophic cardiomyopathy.

Begley DA, Mohiddin SA, Tripodi D, Winkler JB, Fananapazir L.

Pacing Clin Electrophysiol. 2003 Sep;26(9):1887-96.

PMID:
12930505
15.

Defibrillator Versus beta-Blockers for Unexplained Death in Thailand (DEBUT): a randomized clinical trial.

Nademanee K, Veerakul G, Mower M, Likittanasombat K, Krittayapong R, Bhuripanyo K, Sitthisook S, Chaothawee L, Lai MY, Azen SP.

Circulation. 2003 May 6;107(17):2221-6. Epub 2003 Apr 14.

16.

Appropriate evaluation and treatment of heart failure patients after implantable cardioverter-defibrillator discharge: time to go beyond the initial shock.

Mishkin JD, Saxonhouse SJ, Woo GW, Burkart TA, Miles WM, Conti JB, Schofield RS, Sears SF, Aranda JM Jr.

J Am Coll Cardiol. 2009 Nov 24;54(22):1993-2000. doi: 10.1016/j.jacc.2009.07.039. Review.

17.

Trends in treated ventricular fibrillation out-of-hospital cardiac arrest: a 17-year population-based study.

Bunch TJ, White RD, Friedman PA, Kottke TE, Wu LA, Packer DL.

Heart Rhythm. 2004 Sep;1(3):255-9.

PMID:
15851165
18.

Characteristics of ventricular tachyarrhythmias occurring in ischemic versus nonischemic patients implanted with a biventricular cardioverter-defibrillator for primary or secondary prevention of sudden death.

Boriani G, Gasparini M, Lunati M, Santini M, Landolina M, Vincenti A, Curnis A, Bocchiardo M, Padeletti L, Biffi M, Allaria L, Denaro A; InSync ICD Italian Registry Investigators.

Am Heart J. 2006 Sep;152(3):527.e1-11.

PMID:
16923425
19.

Evaluating sex differences in population-based utilization of implantable cardioverter-defibrillators: role of cardiac conditions and noncardiac comorbidities.

MacFadden DR, Tu JV, Chong A, Austin PC, Lee DS.

Heart Rhythm. 2009 Sep;6(9):1289-96. doi: 10.1016/j.hrthm.2009.05.017. Epub 2009 May 18.

PMID:
19695966
20.

Disparities in the use of primary prevention and defibrillator therapy among blacks and women.

Gauri AJ, Davis A, Hong T, Burke MC, Knight BP.

Am J Med. 2006 Feb;119(2):167.e17-21.

PMID:
16443424
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk